Develops and commercializes therapies for rare neurological disorders. Focuses exclusively on the United States market. Now — the numbers.
This is an established company with proven profits.
Average growth of 30% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $535.8M would still be left in the vault — a solid cushion for hard times.
The market pays 15.6× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 89% of them.
Analysts' average target sits 13% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 18% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 30% a year on average.
There is $775.3M in the vault; even if every debt were paid off, $535.8M would remain.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
On our five-subject report card, HRMY sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: HRMY is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.